CNTB Stock Summary and Trading Ideas (Connect Biopharma Hldgs | NASDAQ:CNTB)

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

Connect Biopharma Hldgs trades on the NASDAQ stock market under the symbol CNTB.

As of September 4, 2026, CNTB stock price declined to $1.84 with 2,308,914 million shares trading.

CNTB has a beta of -1.76, meaning it tends to be less sensitive to market movements. CNTB has a correlation of 0.07 to the broad based SPY ETF.

CNTB has a market cap of $115.85 million. This is considered a Micro Cap stock.

Last quarter Connect Biopharma Hldgs reported $3 million in Revenue and -$.27 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.04.

In the last 3 years, CNTB traded as high as $3.82 and as low as $.51.

The top ETF exchange traded funds that CNTB belongs to (by Net Assets): IWO, VTWO, VTWG, RSSL, VTWV.

CNTB has underperformed the market in the last year with a price return of -7.5% while the SPY ETF gained +20.8%. CNTB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -17.5% and -19.3%, respectively, while the SPY returned +2.4% and +1.0%, respectively.

CNTB support price is $1.81 and resistance is $2.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNTB shares will trade within this expected range on the day.